Table 6 Comparison of the annualized medication cost ($US/person) between the "Most costly" COPD patients and the remainder.
From: Determinants of elevated healthcare utilization in patients with COPD
Pharmacological classification | "Most costly"* (n = 98) | The remainder (n = 291) | P value†|
|---|---|---|---|
Total | 709 (420 - 1171) | 340 (191 - 636) | Â |
R- Respiratory System | 242 (118 - 400) | 154 (56 - 330) | 0.01 |
C- Cardiovascular System | 78 (24 - 151) | 15 (1 - 61) | <0.001 |
A- Alimentary Tract & Metabolism | 48 (18 - 103) | 9 (2 - 35) | <0.001 |
J- General Antiinfectives for Systemic Use | 17 (12 - 31) | 12 (6 - 17) | <0.001 |
B- Blood and Blood Forming Organs | 14 (3 - 42) | 1 (0 - 5) | <0.001 |
N- Nervous System | 11 (3 - 40) | 4 (1 - 16) | <0.001 |
   N02- Analgesics | 3.5 (1.5 - 8.5) | 1.3 ( 0.3 - 3.5) | <0.001 |
   N05, N06- Psycholeptics, Psychoanaleptics | 0.8 (0 - 8.6) | 0.2 (0 - 3.7) | 0.02 |
M- Musculo-Skeletal System | 5 (2 - 25) | 4 (1 - 12) | 0.01 |
H- Systemic Hormonal Preparations, Excluding Sex Hormones | 4 (1 - 11) | 1 (0 - 4) | <0.001 |
D- Dermatologicals | 4 (1 - 10) | 2 (0 - 7) | 0.002 |
G- Genitourinary System & Sex Hormones | 3 (0 - 69) | 1 (0 - 17) | 0.05 |
S- Sensory Organs | 3 (1 - 11) | 1 (0 - 5) | <0.001 |
L- Antineoplastic and Immunomodulating Agents | 0 (0 - 0) | 0 (0 - 0) | 0.001 |
P- Antiparasitic Products, Insecticides and Repellants | 0 (0 - 0) | 0 (0 - 0) | <0.001 |